These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

914 related items for PubMed ID: 30352118

  • 1. Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma.
    Sagiv O, Thakar SD, Kandl TJ, Ford J, Sniegowski MC, Hwu WJ, Esmaeli B.
    JAMA Ophthalmol; 2018 Nov 01; 136(11):1236-1241. PubMed ID: 30352118
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series.
    Finger PT, Pavlick AC.
    J Immunother Cancer; 2019 Mar 25; 7(1):83. PubMed ID: 30909967
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
    Afzal MZ, Mabaera R, Shirai K.
    J Immunother Cancer; 2018 Feb 12; 6(1):13. PubMed ID: 29433557
    [Abstract] [Full Text] [Related]

  • 8. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma.
    Indini A, Di Guardo L, Cimminiello C, Prisciandaro M, Randon G, De Braud F, Del Vecchio M.
    J Cancer Res Clin Oncol; 2019 Feb 12; 145(2):511-521. PubMed ID: 30539281
    [Abstract] [Full Text] [Related]

  • 9. Outcomes of Australian patients receiving non-funded anti-PD-1 immune checkpoint inhibitors for non-melanoma cancers.
    Tiu C, Wong A, Herschtal A, Mileshkin L.
    Asia Pac J Clin Oncol; 2018 Aug 12; 14(4):337-342. PubMed ID: 29498208
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Immunotherapy comes of age in octagenarian and nonagenarian metastatic melanoma patients.
    Ben-Betzalel G, Steinberg-Silman Y, Stoff R, Asher N, Shapira-Frommer R, Schachter J, Markel G.
    Eur J Cancer; 2019 Feb 12; 108():61-68. PubMed ID: 30648631
    [Abstract] [Full Text] [Related]

  • 14. Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.
    Lheure C, Hoffmann C, Kramkimel N, Plée J, Franck N, Vanhaecke C, Goldman-Lévy G, Bataillon G, Damotte D, Dupin N, Aractingi S, Grange F, Guégan S.
    Acta Derm Venereol; 2019 Jan 01; 99(1):107-108. PubMed ID: 30176045
    [No Abstract] [Full Text] [Related]

  • 15. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.
    Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV.
    Ann Oncol; 2017 Feb 01; 28(2):368-376. PubMed ID: 27687304
    [Abstract] [Full Text] [Related]

  • 16. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
    Chen L, Douglass J, Kleinberg L, Ye X, Marciscano AE, Forde PM, Brahmer J, Lipson E, Sharfman W, Hammers H, Naidoo J, Bettegowda C, Lim M, Redmond KJ.
    Int J Radiat Oncol Biol Phys; 2018 Mar 15; 100(4):916-925. PubMed ID: 29485071
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Medication use evaluation of programmed death-1 inhibitors in a veteran population.
    Nguyen V, Huq M.
    J Oncol Pharm Pract; 2019 Jul 15; 25(5):1066-1075. PubMed ID: 29726785
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.